Giovanni Marconi
A5025719686- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Histone Deacetylase Inhibitors Research
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Cancer Genomics and Diagnostics
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Hematopoietic Stem Cell Transplantation
- Neutropenia and Cancer Infections
- DNA Repair Mechanisms
- Cancer therapeutics and mechanisms
- Cancer-related Molecular Pathways
- Epigenetics and DNA Methylation
- Cancer, Hypoxia, and Metabolism
- Pneumocystis jirovecii pneumonia detection and treatment
- Immune cells in cancer
- Cancer Treatment and Pharmacology
- Cell death mechanisms and regulation
- Cancer Mechanisms and Therapy
- Immune Cell Function and Interaction
- Molecular Biology Techniques and Applications
- RNA Interference and Gene Delivery
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2018-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2018-2025
University of Bologna
2015-2025
Azienda Unità Sanitaria Locale Della Romagna
2024
Istituto di Ematologia di Bologna
2020-2022
Istituto Oncologico Romagnolo
2015-2022
Medica (Italy)
2019-2020
Policlinico S.Orsola-Malpighi
2015-2019
Mission Bio (United States)
2019
University of Science and Technology of China
2019
Revumenib, an oral, small molecule inhibitor of the menin-lysine methyltransferase 2A (KMT2A) interaction, showed promising efficacy and safety in a phase I study heavily pretreated patients with
Chromothripsis is a one-step genome-shattering catastrophe resulting from disruption of one or few chromosomes in multiple fragments and consequent random rejoining repair. This study defines incidence chromothripsis 395 newly diagnosed adult acute myeloid leukemia (AML) patients three institutions, its impact on survival genomic background. SNP 6.0 CytoscanHD Array (Affymetrix®) were performed all samples. We detected with custom algorithm 26/395 patients. Patients harboring had higher age...
Mesenchymal stromal cells (MSCs) are an essential element of the bone marrow (BM) microenvironment, playing a crucial function in regulating hematopoietic stem cell proliferation and differentiation. Recent findings have outlined putative role for MSCs hematological malignancy development. So far, conflicting results been collected concerning MSC abnormalities acute myeloid leukemia (AML) myelodysplastic syndrome (MDS). In particular, considerable amount evidence has accumulated strongly...
Venetoclax in combination with hypomethylating agents (HMA) is revolutionizing the therapy of acute myeloid leukemia (AML). However, evidence on large sets patients lacking, especially relapsed or refractory leukemia.AVALON a multicentric cohort study that was conducted Italy AML who received venetoclax-based therapies from 2015 to 2020. The approved by ethics committee participating institution and accordance Declaration Helsinki. effectiveness toxicity venetoclax + HMA 190 (43 newly...
Tyrosine kinase inhibitors have improved survival for patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). However, prognosis old or unfit remains poor. In the INCB84344-201 (formerly GIMEMA LAL 1811) prospective, multicenter, phase 2 trial, we tested efficacy and safety of ponatinib plus prednisone in newly diagnosed Ph+ ALL ≥60 years, intensive chemotherapy stem cell transplantation. Forty-four received oral 45 mg/d 48 weeks (core phase), tapered to 60...
Venetoclax (VEN) plus HMA regimen is the standard of care for older adults with AML, however it associated significant myelosuppression and complications, potentially limiting its use in very old. We performed a multi-center retrospective analysis VEN-HMA treatment octo- nonagenarians to further understand tolerability, feasibility, dosing considerations, clinical efficacy this unique group. AML patients 80 years or who received between March 2015 April 2022 were reviewed. was determined by...
Background Aneuploidy occurs in more than 20% of acute myeloid leukemia (AML) cases and correlates with an adverse prognosis. Methods To understand the molecular bases aneuploid (A‐AML), this study examined genomic profile 42 A‐AML 35 euploid (E‐AML) cases. Results was characterized by increased complexity based on exonic variants (an average 26 somatic mutations per sample vs 15 for E‐AML). The integration exome, copy number, gene expression data revealed alterations genes involved DNA...
Despite the recent progress that has been made in understanding and treatment of acute lymphoblastic leukemia (ALL), outcome is still dismal adult ALL cases. Several studies solid tumors identified high expression WEE1 kinase as a poor prognostic factor reported its role cancer-conserving oncogene protects cancer cells from DNA damage. Therefore, targeted inhibition emerged rational strategy to sensitize antineoplastic compounds, which we evaluate this study. The effectiveness selective...
Abstract Background Inotuzumab ozogamicin (IO) has helped to change the treatment paradigm in B‐cell acute lymphoblastic leukemia (B‐ALL) but real‐world data are limited. Methods The INO‐CD22 study is a multicenter retrospective cohort of adult patients with relapsed/refractory B‐ALL treated IO 24 Italian centers from 2014 2019, aim assessing response, survival, and toxicity IO. Results Data for 73 eligible were obtained: median age at start was 52.7 years (I–III quartiles, 51.9–53.5 years),...
Abstract Background The addition of a FLT3 inhibitor (FLT3i) to standard chemotherapy treat fit newly diagnosed (ND) patients with ‐mutated acute myeloid leukemia (AML) represents the care resulting from clinical trial results. However, evidence regarding FLT3i adoption in routine practice is still scarce. Methods Clinical data are reported 394 ND AML enrolled retrospective observational Italian Cohort Study on and treated an upfront intensive regimen (FLT3i group, n = 92) or without (CT...
Although targeting of cell metabolism is a promising therapeutic strategy in acute myeloid leukemia (AML), metabolic dependencies are largely unexplored. We aimed to classify AML patients based on their landscape and map connections between genomic profiles. Combined serum urine metabolomics improved characterization compared with individual biofluid analysis. At intracellular level, displayed dysregulated amino acid, nucleotide, lipid, bioenergetic metabolism. The integration provided...
Introduction: Acute myeloblastic leukemia (AML) is the most frequent type of acute in adults with an incidence 4.2 cases per 100,000 inhabitants and poor 5-year survival. Patients mutations FMS-like tyrosine kinase 3 (FLT3) gene have survival higher relapse rates compared wild-type cases.Areas covered: Several FLT3 inhibitors been proved FLT3mut AML patients, differences their pharmacokinetics, inhibitory adverse events profiles. First-generation multi-kinase (midostaurin, sorafenib,...
Introduction: Screening for synthetic lethality markers has demonstrated that the inhibition of cell cycle checkpoint kinases WEE1 together with CHK1 drastically affects stability and induces death in rapidly proliferating cells. Exploiting this finding a possible therapeutic approach showed efficacy various solid hematologic tumors, though not specifically tested acute lymphoblastic leukemia. Methods: The combination between inhibitors B T precursor leukemia (B/T-ALL) was evaluated vitro ex...
Abstract Artificial Intelligence has the potential to reshape landscape of clinical trials through innovative applications, with a notable advancement being emergence synthetic patient generation. This process involves simulating cohorts virtual patients that can either replace or supplement real individuals within trial settings. By leveraging patients, it becomes possible eliminate need for obtaining consent and creating control groups mimic in active treatment arms. method not only...
Abstract The contribution of the bone marrow (BM) immune microenvironment to acute myeloid leukemia (AML) development is well-known, but its prognostic significance still elusive. Indoleamine 2,3-dioxygenase 1 (IDO1), which negatively regulated by BIN1 proto-oncogene, an interferon-γ-inducible mediator tolerance. With aim develop a IDO1-based gene signature, biological and clinical data 982 patients with newly diagnosed, nonpromyelocytic AML were retrieved from public datasets analyzed using...
Elisa Zuffa1, Eugenia Franchini1, Cristina Papayannidis1, Carmen Baldazzi1, Giorgia Simonetti1, Nicoletta Testoni1, Maria Chiara Abbenante1, Stefania Paolini1, Sartor1, Sarah Parisi1, Giovanni Marconi1, Federica Cattina2, Teresa Bochicchio1, Claudia Venturi1, Emanuela Ottaviani1, Michele Cavo1, Martinelli1 1"Seràgnoli" Institute of Hematology, Sant'Orsola-Malpighi University Hospital, Bologna, Italy 2Bone Marrow Transplant Unit, Brescia, Correspondence to: Papayannidis, e-mail: [email...